Biocept: Samuel Riccitelli, Antonino Morales
Biocept has appointed Samuel Riccitelli as its interim president and CEO and Antonino Morales as its interim CFO. The two hires succeed Michael Nall and Timothy Kennedy, respectively, who resigned their positions on Feb. 15. The firm also named Faye Wilson as lead independent director of the company’s board of directors.
Riccitelli, who remains chair of Biocept's board, joined the firm in October 2020. He has more than 35 years experience in the healthcare industry, including as a member of the board for Orthopediatrics. He also served as CEO of Pathnostics from 2019 to 2020 and as the board chair for Precipio from 2017 to 2019. Prior to that, Riccitelli served as president and CEO of Signal Genetics, as executive VP and chief operating officer of Genoptix, and in number of R&D and general management leadership positions for Becton Dickinson.
Morales, a certified public accountant, has served as a member of Biocept's board since July 2021 and as a member of of the firm's audit committee from August 2021. He served as president and CEO of Apoyo Financiero from June 2017 to March 2020 and has served in multiple senior management or consulting roles with various Fortune 100 companies including Citibank, Bank of America, Arthur Andersen, and Mazda North America.
Biocept said it entered into separation agreements Nall and Kennedy, pursuant to which each of them has agreed to provide the firm with a full release of claims. Biocept has also agreed to provide Nall and Kennedy with the severance benefits they would have been entitled to receive under their respective employment agreements in the event of a termination without cause.